Promise of Structure-Based Drug Design for GPCRs
News May 10, 2012
The review has been published online in Trends in Pharmacological Sciences, a Cell Press publication, and will appear in a special issue of the journal in May, which focuses on structure-based drug design (SBDD).
The authors from Heptares describe how SBDD is becoming the new paradigm for drug discovery targeting GPCRs due to recent technological developments in GPCR stabilisation and novel structural biology. Previously, such approaches were only applicable to soluble enzymes (such as kinases), for which they have now become integrated into the best practices of medicinal chemists. The success of SBDD in developing superior drugs targeting these enzymes has had a significant impact on the pipelines of pharmaceutical companies, leading to the development of multiple marketed drugs and late-stage pipeline candidates.
"The promise of SBDD for GPCRs is that rational design can now be used to identify and optimise ligands that bind challenging or undruggable GPCR targets," said Fiona Marshall, Heptares' Chief Scientific Officer and co-author of the paper. "These small molecules have the potential to offer better potency, selectivity and drug-like properties than previously achievable, establishing a strong basis for the development of much improved medicines for patients."
In the review, the authors discuss how the recent availability of X-ray structures of GPCRs in multiple pharmacologically relevant and ligand-bound conformations, and the subsequent computational analyses of the ligand-binding sites in these conformations, provide a new way to assess the druggability of GPCRs. Druggability is the property of a drug target describing the ease with which a satisfactory small molecule drug may be found which modulates that target in the desired manner. It is a key factor in prioritization of drug discovery targets.
As an example of this, the authors describe Heptares' recent work on the SBDD of A2A antagonists, illustrating how small, potent and selective compounds can be discovered and optimised using virtual screening and receptor-ligand models and X-ray co-structures. A deep druggable region of the A2A binding site revealed by crystallography was targeted and fully exploited to design orally available and efficacious antagonists. A lead candidate in this series is the subject of a global licensing agreement recently announced between Heptares and Shire.
To date, Heptares has applied its GPCR-focused SBDD approach to several other important GPCRs, enabling the assembly of a rich pipeline of novel drug candidates targeting serious neurological (CNS) and metabolic disorders, including: highly selective muscarinic M1 agonists (Alzheimer's disease and cognitive impairment associated with other CNS disorders); dual orexin 1/2 antagonist (chronic insomnia); selective orexin 1 antagonist (addiction and compulsive disorders); allosteric modulators of mGluR5 (autism, Parkinson's disease, depression and anxiety); GLP-1 agonist (Type 2 diabetes); and CXCR-4 antagonists (cancer/HIV).
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE